Tempus AI, Inc. $TEM Shares Bought by Pictet Asset Management Holding SA

Key Points

• Pictet Asset Management Holding SA boosted its stake in Tempus AI by 291.3% in Q4, acquiring 36,096 additional shares to hold 48,488 shares worth about $2.95 million.
• Analyst coverage is mixed but tilted positive: MarketBeat shows a consensus rating of "Moderate Buy" with a consensus target price of $71.36, while individual price targets range from about $60 to $90+ after recent revisions.
• Company insiders have been net sellers recently — CEO Eric Lefkofsky sold 166,250 shares under a Rule 10b5‑1 plan for roughly $8.5 million, and insiders sold 563,471 shares (≈$29.8M) over the last 90 days.

Pictet Asset Management Holding SA grew its stake in Tempus AI, Inc. (NASDAQ:TEM - Free Report) by 291.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 48,488 shares of the company's stock after acquiring an additional 36,096 shares during the quarter. Pictet Asset Management Holding SA's holdings in Tempus AI were worth $2,948,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the stock. Victory Capital Management Inc. increased its position in Tempus AI by 1.5% during the 3rd quarter. Victory Capital Management Inc. now owns 11,078 shares of the company's stock worth $894,000 after purchasing an additional 162 shares in the last quarter. Global Retirement Partners LLC lifted its holdings in Tempus AI by 29.5% in the 3rd quarter. Global Retirement Partners LLC now owns 733 shares of the company's stock valued at $59,000 after purchasing an additional 167 shares in the last quarter. US Bancorp DE boosted its stake in shares of Tempus AI by 6.6% during the 3rd quarter. US Bancorp DE now owns 2,848 shares of the company's stock worth $230,000 after purchasing an additional 176 shares during the last quarter. Legacy Bridge LLC boosted its stake in shares of Tempus AI by 1.6% during the 4th quarter. Legacy Bridge LLC now owns 12,418 shares of the company's stock worth $733,000 after purchasing an additional 193 shares during the last quarter. Finally, Farther Finance Advisors LLC grew its holdings in shares of Tempus AI by 3.5% during the fourth quarter. Farther Finance Advisors LLC now owns 6,390 shares of the company's stock worth $377,000 after buying an additional 219 shares in the last quarter. Institutional investors and hedge funds own 24.22% of the company's stock.

Analysts Set New Price Targets

TEM has been the topic of several recent analyst reports. Needham & Company LLC reissued a "buy" rating and set a $75.00 price objective on shares of Tempus AI in a research note on Wednesday, March 11th. TD Cowen raised shares of Tempus AI from a "hold" rating to a "buy" rating and set a $65.00 target price for the company in a research note on Monday, April 13th. BTIG Research cut their price target on Tempus AI from $105.00 to $90.00 and set a "buy" rating for the company in a report on Wednesday, February 25th. Morgan Stanley reduced their price target on Tempus AI from $85.00 to $70.00 and set an "overweight" rating on the stock in a research note on Tuesday, March 3rd. Finally, JPMorgan Chase & Co. decreased their price objective on Tempus AI from $80.00 to $60.00 and set a "neutral" rating on the stock in a report on Wednesday, February 25th. Nine investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $71.36.

Tempus AI Trading Up 0.0%

Shares of TEM stock opened at $55.02 on Monday. The firm's 50-day simple moving average is $50.65 and its 200-day simple moving average is $63.17. The company has a debt-to-equity ratio of 2.52, a current ratio of 3.13 and a quick ratio of 3.00. Tempus AI, Inc. has a 1-year low of $41.73 and a 1-year high of $104.32. The firm has a market cap of $9.84 billion, a P/E ratio of -39.02 and a beta of 4.00.

Key Stories Impacting Tempus AI

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Named to TIME’s 2026 list and expanded clinical reach via a multi‑year collaboration with Keck/USC — boosts brand credibility, supports commercial adoption of Tempus’ AI precision‑medicine tools and expands addressable clinical volume (coverage cites TIME recognition and the Keck Medicine partnership). TIME recognition article Keck partnership article
• Positive Sentiment: Investor‑day visibility and bullish coverage — upcoming Investor Day (management roadmap) and fresh bull writeups may attract momentum buyers and reduce execution uncertainty if management delivers concrete commercialization milestones. Investor day / bull case coverage
• Neutral Sentiment: CEO Eric Lefkofsky sold 166,250 shares under a pre‑arranged Rule 10b5‑1 plan — provides liquidity/estate planning context but can be interpreted variably by the market; sale was disclosed in an SEC filing. SEC Form 4 disclosure
• Neutral Sentiment: Analyst/valuation mix — some firms trimmed fair‑value slightly and note the recent rally may be a short‑term bounce; coverage is polarized (buy/hold/sell), so flows depend on upcoming execution/metrics. Analyst narrative article
• Negative Sentiment: Class action litigation over genetic data collection in an acquisition — proposed suits raise legal, compliance and remediation cost risk that can pressure sentiment until resolved. Class action article
• Negative Sentiment: Peer comparisons favor Illumina (ILMN) on valuation and earnings outlook — could divert institutional allocation away from TEM if investors prefer a more established genomics exposure. Peer comparison article

Insider Activity

In other Tempus AI news, CEO Eric P. Lefkofsky sold 166,250 shares of the stock in a transaction that occurred on Tuesday, April 28th. The shares were sold at an average price of $51.13, for a total transaction of $8,500,362.50. Following the transaction, the chief executive officer owned 8,841,783 shares of the company's stock, valued at $452,080,364.79. This trade represents a 1.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Erik Phelps sold 9,464 shares of Tempus AI stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $59.43, for a total transaction of $562,445.52. Following the completion of the transaction, the executive vice president owned 79,816 shares in the company, valued at approximately $4,743,464.88. This trade represents a 10.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 563,471 shares of company stock valued at $29,837,342 in the last ninety days. 24.26% of the stock is owned by company insiders.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company's core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.